An Open- Label, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Signals of DUR-928 in Patients With Alcoholic Hepatitis
Phase of Trial: Phase II
Latest Information Update: 01 Mar 2018
At a glance
- Drugs DUR 928 (Primary)
- Indications Alcoholic hepatitis
- Focus Adverse reactions
- Sponsors DURECT Corporation
- 01 Mar 2018 Status changed from not yet recruiting to recruiting according to a DURECT Corporation media release.
- 01 Mar 2018 According to a DURECT Corporation media release, data from this trial are expected in 2018.
- 15 Feb 2018 New trial record